Literature DB >> 1468429

Pharmacokinetics of loracarbef and interaction with acetylcysteine.

S Roller1, H Lode, I Stelzer, K M Deppermann, M Boeckh, P Koeppe.   

Abstract

A study was conducted to evaluate the pharmacokinetics of loracarbef, a new synthetic oral carbacephem antibiotic, following administration of 400 mg in normal male volunteers. The influence of food and possible interaction with acetylcysteine, a commonly used mucolytic agent, was also studied. Twelve healthy volunteers participated in the study and randomly received an oral dose of 400 mg loracarbef in the fasting state, 400 mg loracarbef following a standard breakfast or 400 mg loracarbef together with 200 mg acetylcysteine in granular form. Serum and urine concentrations were determined over 24 h by means of a bioassay. Loracarbef was well tolerated. Four volunteers complained of mild, transient headache. The substance was well absorbed with a mean peak level of 19.21 +/- 3.94 mg/l in the fasting state; it was primarily excreted in active form via the kidneys (urine recovery/24 h: 86-92%). The elimination half-life ranged from 70.3 to 102.0 min. Acetylcysteine had no effect on the absorption of loracarbef. The intake together with food delayed the absorption time, but had no influence on the bioavailability.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1468429     DOI: 10.1007/bf01960891

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

1.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

2.  [The effect of N-acetyl-L-cystein (Mucosolvin) on different antibiotics].

Authors:  B Gottschalk; G Wichmann
Journal:  Dtsch Gesundheitsw       Date:  1970-04-16

3.  New regression function for absorption kinetics.

Authors:  P Koeppe
Journal:  Arzneimittelforschung       Date:  1988-09

4.  In vitro susceptibilities of common pediatric pathogens to LY163892.

Authors:  S Shelton; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

5.  In vitro activities of LY163892, cefaclor, and cefuroxime.

Authors:  C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 6.  The influence of food on the absorption of antimicrobial agents.

Authors:  P G Welling; F L Tse
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

7.  Effect of route of administration and distribution on drug action.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

Review 8.  Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review.

Authors:  K Stoeckel; Y K Tam; J Kneer
Journal:  Curr Med Res Opin       Date:  1989       Impact factor: 2.580

9.  Some observations on the penetration of antibiotics through mucus in vitro.

Authors:  B A Saggers; D Lawson
Journal:  J Clin Pathol       Date:  1966-07       Impact factor: 3.411

10.  Combined cefuroxime plus acetylcysteine in the treatment of bacterial infections of the respiratory tract.

Authors:  E Bonavita
Journal:  Drugs Exp Clin Res       Date:  1985
View more
  4 in total

1.  The effect of four different types of diet on the bioavailability of loracarbef.

Authors:  A T Bapujee; T Singh; T Ahmed; T Monif; N Saha; P L Sharma
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Oct-Dec       Impact factor: 2.441

Review 2.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 3.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.